Introduction {#sec1_1}
============

Despite the many technological advances in both haemodialysis and peritoneal dialysis over the years \[[@B1],[@B2]\], the mortality of chronic kidney disease patients treated by dialysis (CKD5d) remains disappointingly high, with some studies reporting 5-year survival rates similar to those of patients with solid organ malignancies \[[@B3],[@B4]\]. Although CKD5d patient mortality varies between countries, mortality rates do appear to be falling \[[@B5]\].

Haemodialysis and peritoneal dialysis treatments differ fundamentally in terms of one being an intermittent therapy, with marked changes in volume status and fluctuating blood pressure, whereas the other modality is continuous. Despite these differences, mortality is similar with both modalities \[[@B6]\], with only a few reports suggesting a marginal benefit for those patients choosing peritoneal dialysis \[[@B7]\]. As with haemodialysis, cardiovascular disease remains the commonest cause of death for peritoneal dialysis patients \[[@B8]\].

Although there are many potential cardiovascular risk factors for the dialysis patient, including both conventional (including smoking, hypertension, diabetes mellitus, hypercholesterolaemia and left ventricular hypertrophy) and CKD-specific risk factors (including anaemia, hyperphosphataemia and hyperhomocysteinaemia), there has been recent interest in the role of hypervolaemia as a cardiovascular risk factor \[[@B9]\]. Haemodialysis patients accumulate fluid between dialysis sessions, and more recently with the introduction of bioimpedance assessments it is now recognised that peritoneal dialysis patients may also be volume overloaded \[[@B10],[@B11]\]. We therefore decided to audit volume status in haemodialysis and peritoneal dialysis patients attending our university hospital dialysis centre, to compare volume status in these two groups.

Patients and Methods {#sec1_2}
====================

We studied 72 healthy adult haemodialysis patients attending our university hospital outpatient haemodialysis units for thrice weekly haemodialysis treatments, using high-flux haemodialysers, and 115 healthy peritoneal dialysis patients attending for routine outpatient assessment, with 33% prescribed hypertonic glucose exchanges (22.7 g/l glucose) and \>95% icodextrin. All patients had bioimpedance assessments, these were made prior to the midweek dialysis session and then 20 min after dialysis for the haemodialysis cohort to allow for re-equilibration \[[@B12]\], and following a standard peritoneal equilibrium test for the peritoneal dialysis group \[[@B13]\]. As such, pregnant patients, those with amputations and cardiac pacemakers or defibrillators were excluded from the study as bioimpedance measurements were not made. Volume and body composition measurements were made using a direct multi-frequency bioelectrical impedance (MF-BIA) analysis method using an eight hand and feet tactile electrode system (Biospace in body 720, Seoul, South Korea) \[[@B14]\]. Height was measured by a standard wall mounted measure (Sigmeas 1, Doherty signature range, [www.mediclick.co.uk](http://www.mediclick.co.uk)).

Serum biochemistry samples were analysed with a standard multi-channel biochemical analyser (Roche Integra, Roche Diagnostics, Lewes, UK), using the bromcresol green method for albumin determination; N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured by immunoassay (ECLIA Roche Diagnostics, GMBH, Mannheim, Germany) and NT-proBNP samples were taken after the midweek dialysis session \[[@B15]\]. 24-hour urine collections were analysed to determine urine volume and sodium content. Routine chest X-rays and standard two-dimensional transthoracic echocardiograms (Philips IE33, Philips Medical Systems, The Netherlands, [www.healthcare.philips.com](http://www.healthcare.philips.com)) were reviewed.

Ethical approval was granted by the local ethical committee as audit and clinical service development.

Statistical Analysis {#sec2_1}
--------------------

Statistical analysis was by Student\'s t test for normally distributed data and Mann-Whitney U test for nonparametric data (GraphPad Prism version 4.0, San Diego, Calif., USA). In addition χ^2^ analysis with correction for small numbers and analysis of variance with post-analysis correction were also performed using SPSS software for Windows version 15.0 (SPSS Inc., Chicago, Ill., USA). Data are expressed as mean ± SE, median and interquartile range, or percentages. Statistical significance was taken at or below the 5% level.

Results {#sec1_3}
=======

There was no difference in age between the haemodialysis cohort (55.0 ± 0.0 years) and the peritoneal dialysis cohort (55.4 ± 1.4 years), or sex distribution (50% male vs. 44.4% male, respectively). However, there were more diabetics in the haemodialysis cohort (36.1 vs. 20%; χ^2^ 5.14, p = 0.023), and more patients were prescribed insulin (20.8 vs. 9.1%; χ^2^ 4.61, p = 0.31). However, there were no differences in dialysis vintage \[median 22 (4.5--39) vs. 25 (3--43) months\], or race (54.2 vs. 57.4% Caucasoids). As expected the haemodialysis patients had weight reduction with dialysis, but there was no difference in weight compared to the peritoneal dialysis cohort (table [1](#T1){ref-type="table"}). Body composition was similar in the two groups (table [1](#T1){ref-type="table"}). Urine output was greater in the peritoneal dialysis group \[median 1,075 (485--1,613) vs. 42.5 (0--1,010) ml/day, p \< 0.001\], as was urinary sodium excretion \[57 (13--99) vs. 0 (0--61) mmol/day, p \< 0.001\], and more were prescribed diuretics (77.4 vs. 38.9%; χ^2^ 4.95, p = 0.026). However, similar numbers were prescribed anti-hypertensives (63.5 vs. 76.4%), and the median number of anti-hypertensives prescribed was not different \[1 (0--2) vs. 1 (1--2)\].

Just \>30% of the peritoneal dialysis group had a ratio of extracellular water to total body water (ECW/TBW) above the normal reference range of 0.36--0.40, which was similar to the pre-haemodialysis cohort (fig. [1](#F1){ref-type="fig"}). The ECW/TBW ratios were higher in the peritoneal dialysis group compared to those after haemodialysis (table [1](#T1){ref-type="table"}). Serum sodium was lower in the peritoneal dialysis group, and C-reactive protein higher in the haemodialysis cohort, with just under half the haemodialysis cohort dialysing with central venous access catheters. NT-proBNP levels (table [2](#T2){ref-type="table"}), cardiac dimensions on chest X-ray and transthoracic echocardiography were not different (table [3](#T3){ref-type="table"}).

Discussion {#sec1_4}
==========

It is readily accepted that the majority of patients attending for outpatient haemodialysis are volume overloaded and require ultrafiltration during a haemodialysis session. In our study of asymptomatic stable peritoneal dialysis patients attending for routine assessments of peritoneal dialysis adequacy and transport status (who were not thought to be clinically volume overloaded), volume status assessed by MF-BIA was similar to that of patients prior to haemodialysis, supporting earlier smaller studies \[[@B16]\]. Thus, despite greater urine output and urinary sodium excretion peritoneal dialysis patients are similarly volume overloaded as haemodialysis patients.

The results of MF-BIA depend upon the resistance and reactance to the passage of an electrical current, and our MF-BIA device has been validated in both healthy controls \[[@B17],[@B18]\] and haemodialysis \[[@B14]\] and peritoneal dialysis patients \[[@B19]\]. MF-BIA is affected by body composition which changes with age, sex and race \[[@B20]\], and as such it has been suggested that volumes should be corrected for height \[[@B21]\] or body surface area \[[@B22]\]. Volume overload in incident peritoneal dialysis patients is known to adversely determine outcome; however, it is not generally recognised that peritoneal dialysis patients are chronically volume overloaded \[[@B23]\]. However, we did not find any differences in ECW, or when corrected for height or body surface area with the haemodialysis group, either before or after haemodialysis. Other reports have reported that ECW is greater in peritoneal dialysis patients compared to after dialysis \[[@B24]\]. This was a smaller study of predominantly Caucasoid patients with fewer diabetics. However, an increased ECW/TBW ratio can also be caused by a reduction in TBW due to a loss of intracellular water (ICW). Nearly all our peritoneal dialysis patients used icodextrin, which can increase plasma osmolality \[[@B25]\], due to the accumulation of metabolites \[[@B26]\], and could therefore potentially lead to water removal from and reduction in ICW. Another possible cause of a reduction is ICW protein energy malnutrition \[[@B27]\]. However, in our study both NT-proBNP values, a marker of extracellular volume expansion \[[@B15]\], and ECHO cardiography dimensions were not different between the peritoneal and haemodialysis groups, in keeping with the changes in ECW/TBW which were due to ECW expansion, and not ICW loss. This is supported by body composition which was similar between the groups in terms of skeletal muscle and fat mass. As such, the ECW/TBW in the peritoneal dialysis patients cannot be explained by a loss of ICW and supports ECW expansion.

The lower serum albumin and sodium in the peritoneal dialysis group could be due to volume overload and dilution, and one previous study showed that serum albumin concentrations increased following deliberate ultrafiltration \[[@B28]\]. The lower sodium, however, could also be an artefact of laboratory error \[[@B29]\] due to the usage of icodextrin \[[@B26],[@B30]\].

As expected, blood pressure fell after haemodialysis \[[@B31]\], but pre-dialysis blood pressure was not different compared to the peritoneal dialysis cohort. However, both post-dialysis mean arterial pressure and diastolic blood pressure were lower than those in the peritoneal dialysis group. Both groups had similar antihypertensive medication prescription, although more peritoneal dialysis patients were prescribed loop diuretics, reflecting greater urine volumes. In keeping with blood pressure, transthoracic echocardiography assessments of cardiac size were similar between the groups, as were NT-proBNP levels. It could be speculated that as NT-proBNP is degraded by the kidney, then levels should have been lower in the peritoneal dialysis group due to better residual renal function.

After peritonitis \[[@B32]\], ultrafiltration failure and clinically apparent volume overload are the next most common causes of peritoneal dialysis technique failure \[[@B33]\]. Our study shows that stable asymptomatic peritoneal dialysis patients are equally volume overloaded when compared to haemodialysis patients. As such, this chronic volume overload may account for the prevalence of hypertension and increased cardiovascular death rate in this group of patients \[[@B33]\].
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![ECW/TBW ratio in haemodialysis (HD) patients attending for midweek haemodialysis session (pre- and post-HD values), and peritoneal dialysis (PD) patients with peritoneal dialysate drained out. \* p \< 0.05; \*\* p \< 0.01 vs. PD patients.](nne-0002-0048-g01){#F1}

###### 

Peritoneal dialysis patients before haemodialysis and a minimum of 20 min after haemodialysis to allow for redistribution

                             PD              pre-HD          post-HD
  -------------------------- --------------- --------------- -----------------------------------------------------
  Patients, n                115             72              72
  Weight, kg                 70.1 ± 1.4      68.8 ± 1.7      66.9 ± 1.7
  BMI                        25.7 ± 0.4      25.3 ± 0.7      24.7 ± 0.7
  BSA, m^2^                  1.77 ± 0.02     1.74 ± 0.03     1.72 ± 0.03
  SBP, mm Hg                 140.7 ± 2.3     147.2 ± 3.3     138.0 ± 3.0
  DBP, mm Hg                 81.8 ± 1.4      79.4 ± 0.4      75.6 ± 0.3[^\*\*^](#T1F2){ref-type="table-fn"}
  MAP, mm Hg                 101.6 ± 1.5     102.1 ± 2.4     96.4 ± 2.1[^\*^](#T1F1){ref-type="table-fn"}
  ICW, l/1.73 m^2^           20.92 ± 0.27    21.64 ± 0.37    21.05 ± 0.39[^\*^](#T1F1){ref-type="table-fn"}
  ECW, l/1.73 m^2^           13.68 ± 0.19    14.04 ± 0.23    13.21 ± 0.21
  ECW/TBW                    0.393 ± 0.001   0.394 ± 0.001   0.389 ± 0.004[^\*\*\*^](#T1F3){ref-type="table-fn"}
  Fat mass, kg               21.9 ± 0.9                      19.5 ± 1.3
  Skeletal muscle mass, kg   26.1 ± 0.6                      25.6 ± 0.8
  Body fat, %                30.6 ± 0.9                      26.5 ± 1.5
  Waist:hip ratio            0.94 ± 0.01                     0.95 ± 0.01

PD = Peritoneal dialysis patients; HD = haemodialysis patients; BMI = body mass index; BSA = body surface area; SBP = systolic blood pressure; DBP = diastolic blood pressure; MAP = mean arterial blood pressure; ICW = intracellular water; ECW = extracellular water.

p \< 0.05 vs. PD;

p \< 0.01 vs. PD;

p \< 0.001 vs. PD.

###### 

Peritoneal dialysis patients before and after haemodialysis

                      PD                  pre-HD                                               post-HD
  ------------------- ------------------- ---------------------------------------------------- ----------------------------------------------------
  Sodium, mmol/l      138 ± 0.3           139.8 ± 0.35[^\*\*\*^](#T2F3){ref-type="table-fn"}   140.7 ± 0.23[^\*\*\*^](#T2F3){ref-type="table-fn"}
  Calcium, mmol/l     2.29 ± 0.02         2.28 ± 0.04                                          2.15 ± 0.02[^\*\*^](#T2F2){ref-type="table-fn"}
  Glucose, mmol/l     6.4 ± 0.3           7.6 ± 1.0                                            6.8 ± 0.2
  Albumin, g/l        39.7 ± 0.9          40.5 ± 0.5                                           43.6 ± 0.7[^\*\*^](#T2F2){ref-type="table-fn"}
  CRP, mg/l           3 (1--10)           5 (2--13)[^\*^](#T2F1){ref-type="table-fn"}          
  PTH, pmol/l         23.4 (13.8--40.3)   20.2 (8.8--44.6)                                     
  NT-proBNP, pmol/l   242 (90--688)                                                            251 (118--606)

PD = Peritoneal dialysis patients; HD = haemodialysis patients; Calcium = corrected serum calcium; CRP = C-reactive protein; PTH = parathyroid hormone.

p \< 0.05 vs. PD;

p \< 0.01 vs. PD;

p \< 0.001 vs. PD.

###### 

Transthoracic echocardiographic examinations of haemodialysis and peritoneal dialysis patients

                          PD             HD
  ----------------------- -------------- --------------
  CTR                     0.47 ± 0.007   0.49 ± 0.008
  LVEDD, cm               4.69 ± 0.07    4.55 ± 0.08
  LVES, cm                3.08 ± 0.07    3.15 ± 0.1
  IVSD, cm                1.2 ± 0.02     1.2 ± 0.02
  PWD, cm                 1.13 ± 0.12    1.14 ± 0.02
  LASD, cm                4.0 ± 0.14     3.95 ± 0.09
  Ejection fraction, %    57.7 ± 0.9     56.2 ± 1.3
  RVSP, mm Hg             25.9 ± 1.4     27.7 ± 1.2
  Diastolic dysfunction   1 (1--1)       1 (0--1)
  Systolic dysfunction    0 (0--0)       1 (0--1)

PD = Peritoneal dialysis patients; HD = haemodialysis patients; CTR = cardiothoracic ratio from departmental chest X-ray; LVEDD = left ventricular end-diastolic diameter; LVES = left ventricular end-systolic diameter; IVSD = intraventricular septal diameter; PWD = posterior wall diameter; LASD = left atrial end-systolic diameter; RVSP = estimated right ventricular end-systolic pressure; Diastolic/Systolic dysfunction = left ventricular diastolic and systolic dysfunction.
